Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + rifabutin
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antibiotic therapy consisting of azithromycin (a macrolide antibiotic) and rifabutin (a rifamycin derivative). This combination is primarily used for the prevention and treatment of Mycobacterium avium complex (MAC) infections in immunocompromised patients, particularly those with HIV infection. The combination has shown greater efficacy than rifabutin alone in preventing MAC infections, though it is associated with significant tolerability issues including gastrointestinal symptoms and neutropenia.
02
Targets
Beyond the preview
Go deeper on azithromycin + rifabutin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + rifabutin.